© 2021 BioMarin. All rights reserved.

Victoria Sluzky, Ph.D., joined BioMarin in 2003 and serves as Senior Vice President of Technical Development. In this role, Dr. Sluzky leads a cross-functional department which focuses on all aspects of product development covering the transition from discovery to commercial manufacturing and regulatory approvals.  Technical Development includes Process Sciences (Cell culture and Purification Process Development; Analytical Sciences; Chemical, Formulation and Device Development; and PS Innovation), Regulatory Strategy Implementation and Product Quality Leaders.  While at BioMarin, Dr. Sluzky has been responsible for supporting the Chemistry, Manufacturing and Controls (CMC) systems for seven commercial products and more than 12 clinical programs.

Prior to joining BioMarin, Dr. Sluzky worked as Director, Analytical Development at Onyx Pharmaceuticals, where she contributed to the development of adenovirus-based oncolytic viruses. Previous roles include work in Analytical Development at COR Therapeutics, focusing on analytical and formulation development for peptides, small molecules and proteins, as well as a Scientist, Pharmaceutical Development at Scios, focusing on protein formulation and analytical development.

In addition to authoring multiple CMC documents used for regulatory submissions and inspections, Dr. Sluzky participates in industry forums and frequent interactions with regulatory authorities.   She holds one patent and has authored nine scientific publications. Dr. Sluzky earned a B.S. degree in chemical engineering from Stanford University and a Ph.D. in chemical engineering with a minor in Business Administration from Massachusetts Institute of Technology. She is a Fellow of the American Institute for Medical and Biomedical Engineering (AIMBE) and a member of the American Association of Pharmaceutical Scientists (AAPS) and the California Separation Sciences Society (CaSSS).

Our Pipeline

We take on the biggest challenges in rare disease.

Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address.

View Now Our Pipeline